SLAOT 2016

SLAOT 2016
Punta Cana, República Dominicana

viernes, 22 de noviembre de 2013

Calcanail , internal fixation device for calcaneal fractures

Femoral and tibial component rotation in total knee arthroplasty methods and consequences

http://www.bjj.boneandjoint.org.uk/content/95-B/11_Supple_A/140.abstract

Femoral and tibial component rotation in total knee arthroplasty

methods and consequences

  1. R. D. Scott, MD, Professor of Orthopaedic Surgery 1
+Author Affiliations
  1. 1Harvard Medical School , Suite 560, 125 Parker Hill Ave, Boston, Massachusetts 02120, USA.
  1. Correspondence should be sent to Dr R. D. Scott; e-mail:rdscottmd@gmail.com

Abstract

At least four ways have been described to determine femoral component rotation, and three ways to determine tibial component rotation in total knee replacement (TKR). Each method has its advocates and each has an influence on knee kinematics and the ultimate short and long term success of TKR. Of the four femoral component methods, the author prefers rotating the femoral component in flexion to that amount that establishes a stable symmetrical flexion gap. This judgement is made after the soft tissues of the knee have been balanced in extension.
Of the three tibial component methods, the author prefers rotating the tibial component into congruency with the established femoral component rotation with the knee is in extension. This yields a rotationally congruent articulation during weight-bearing and should minimise the torsional forces being transferred through a conforming tibial insert, which could lead to wear to the underside of the tibial polyethylene. Rotating platform components will compensate for any mal-rotation, but can still lead to pain if excessive tibial insert rotation causes soft-tissue impingement.
Cite this article: Bone Joint J 2013;95-B, Supple A:140–3.

Footnotes

  • No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
    This paper is based on a study which was presented at the 29th Annual Winter 2012 Current Concepts in Joint Replacement® meeting held in Orlando, Florida, 12th – 15th December.
  • Received August 20, 2013.
  • Accepted August 21, 2013.

Home Exercise DVD Promotes Exercise Accuracy by Caregivers of Children and Adolescents With Brachial Plexus Palsy

http://www.physiospot.com/research/home-exercise-dvd-promotes-exercise-accuracy-by-caregivers-of-children-and-adolescents-with-brachial-plexus-palsy/


Home Exercise DVD Promotes Exercise Accuracy by Caregivers of Children and Adolescents With Brachial Plexus Palsy

Home Exercise DVD Promotes Exercise Accuracy by Caregivers of Children and Adolescents With Brachial Plexus Palsy
The researchers’ aim for this study evaluate the accuracy of home exercise performance by caregivers of children with neonatal brachial plexus palsy (NBPP) who use digital versatile disc (DVD) guidance. They conducted this prospective cohort study at the Brachial Plexus Clinic at the University of Michigan. The study consisted of 77 adult caregivers of a consecutive cohort of pediatric patients with NBPP. The participants received the Home Exercise Program for Brachial Plexus Palsy DVD and an initial demonstration of proper hand placement and movement patterns by 1 of 2 occupational therapists. At times A, B, and C (approximately 3, 6, and 12 months), caregiver accuracy in exercise performance at each joint and standard measurements of arm function were recorded. Caregiver accuracy in correct hand placement and movement pattern during exercise performance was evaluated with use of a dichotomy scale (yes/no) at each joint. Active and passive range of motion were assessed as indicators of arm function. The mean patient age was 38 months, and the median Narakas score was 2. No significant difference in exercise accuracy for all upper extremity joints between the initial evaluation and times A, B, and C or between individual times was observed, except at the shoulder (98.9% initially to 88.3% at time A; P = .0002) and elbow (100% initially to 96.6% at time A; P = .04). As for arm function, they observed an increase in active range of motion for shoulder flexion, elbow flexion, forearm supination, wrist extension, and finger flexion during the study period.
Their study concluded that shoulder and elbow exercises could be more complicated and require more frequent performance review with the caregiver. However, the home exercise DVD may benefit patients with NBPP and their caregivers and could offer an adjunct to formal therapy sessions.

- See more at: http://www.physiospot.com/research/home-exercise-dvd-promotes-exercise-accuracy-by-caregivers-of-children-and-adolescents-with-brachial-plexus-palsy/#sthash.FXIj8CIv.dpuf

Artroscopia y ortopedia: Viscosupplementation for Knee Osteoarthritis



Artroscopia y ortopedia: Viscosupplementation for Knee Osteoarthritis: http://www.arthritis-health.com/treatment/injections/viscosupplementation-knee-osteoarthritis Viscosupplementation is a medical procedur...
Viscosupplementation for Knee Osteoarthritis

http://www.arthritis-health.com/treatment/injections/viscosupplementation-knee-osteoarthritis
Viscosupplementation is a medical procedure during which lubricating fluid is injected into a joint. Also called hyaluronic acid injections or hyaluronan injections, viscosupplementation is most commonly used to treat symptoms of knee osteoarthritis.
Hyaluronic acid is a key component of the joint fluid in healthy joints, but is found in lower concentrations in osteoarthritic joints
By adding hyaluronic acid to the existing joint fluid of an osteoarthritic knee, the goal is to:
Facilitate better knee movement
Reduce pain
Perhaps slow osteoarthritis progression
Typical candidates for viscosupplementation are people with knee osteoarthritis who have failed to improve with other non-surgical treatments.
Following the injections, it is generally recommended that patients engage in a rehabilitation program that includes gentle, progressive knee exercise. The goals of rehabilitation are to improve range of motion and develop muscle strength to support the knee.

Cirugía de la Mano y Microcirugía: Premios Semergen (I): lesiones en la práctica prof...

Cirugía de la Mano y Microcirugía: Premios Semergen (I): lesiones en la práctica prof...: http://www.condroprotectores.es/premios-semergen-i-lesiones-en-la-practica-profesional-de-la-guitarra/ BECAS Y PREMIOS Viernes 22 de ...

Premios Semergen (I): lesiones en la práctica profesional de la guitarra


183894486Conocer la incidencia de lesiones en la práctica profesional de la guitarra y determinar las posibles causas que contribuyen a su aparición. Este fue el objetivo de un estudio descriptivo realizado por la Dra. Milagros Lucas, Médico Residente de Medicina Familiar y Comunitaria del Centro de Salud San Fernando de Badajoz. El trabajo ha sido premiado con una de las becas a la investigación en artrosis y condroprotección que Semergen otorgó durante su congreso nacional el pasado mes de octubre.

sábado, 16 de noviembre de 2013

Reumails. Reumatología al día: Seguridad y eficacia del biosimilar CT-P13 compara...



Reumails. Reumatología al día: Seguridad y eficacia del biosimilar CT-P13 compara...: Pak y colaboradores han publicado bajo la modalidad de acceso abierto uno de los primeros estudios comparativos en fase 1 que pone a prueb...
Seguridad y eficacia del biosimilar CT-P13 comparado con Infliximab en pacientes con Espondilitis Anquilosante

Pak y colaboradores han publicado bajo la modalidad de acceso abierto uno de los primeros estudios comparativos en fase 1 que pone a prueba el producto CT-P13, un biosimilar al Infliximab (IFX) frente a la molécula originalmente patentada en términos de farmacocinecia, seguridad y efectividad.


Se trata de un estudio doble ciego, randomizado que involucró 46 centros de 10 países de Europa, Asia y Latinoamérica y que enroló a 250 pacientes bajo la modalidad de seguimiento paralelo grupal (125 en cada rama).
La selección de pacientes se hizo según los criterios modificados de Nueva York (1984), exigiéndose un diagnóstico al menos 3 meses antes de iniciado el screening, con un BASDAI mayor o igual a 4 y un puntaje de dolor axial mayor o igual a 4/10.
Los pacientes recibieron una dosis de 5mg/Kg de CT-P13 o IFX según el brazo de aleatorización en las semanas 0, 2, 6 y luego cada 8 semanas hasta la semana 30.


Los autores decidieron incluir en los parámetros farmacocinéticos habituales a la repuesta ASAS20 y ASAS40.
Los resultados del estudio se estratificaron de la siguiente forma:


Concentración en sangre. Se usó, para establecer la comparativa entre los dos fármacos, el área bajo la curva de concentración el tiempo una vez alcanzado el estado de equilibrio. CT-P13 presentó niveles de 147 ugh/mL mientras que el IFX alcanzó cifras de 144.8 ugh/mL.
La respuesta ASAS20 fue del 70.5% en los pacientes que recibieron CT-P13 y 72.4% en los que recibieron IFX mientras que la respuesta ASAS40 fue del 51.8% en los que recibieron CT-P13 y 47.4% en los que recibieron IFX.
Los parámetros de seguridad fueron similares en los dos grupos de pacientes.
En cuanto a la producción de anticuerpos anti-infliximab, se detectaron en 9.1% de los pacientes con enfermedad activa que recibieron CT-P13 y en 11.0% de los que recibieron IFX, una vez alcanzada la semana 14. En la semana 30, las proporciones respectivas fueron 27.4% y 22.5%.


Se trata de un estudio comparativo cuyos resultados plantean alentar la confianza sobre el uso del CT-P13 en pacientes con EA. La selección de pacientes ha conseguido dos cohortes muy similares en su situación basal y por otra parte, al diseño metodológico no se le pueden hacer observaciones salvo quizás de índole de expectativa de respuesta ASAS, no obstante esta es la misma para ambos fármacos. Creemos que este artículo sentará precedente en los diseños de investigación de otras molécular que pretendan demostrar su equivalencia con terapias biológicas actualmente empleadas.


Referencia:
Won Park,Pawel Hrycaj, Slawomir Jeka,Volodymyr Kovalenko, et al.A randomised, double-blind, multicentre,parallel group, prospective study comparing thepharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosingspondylitis: the PLANETAS study. Ann Rheu Dis 2013: 72:1605–1614